ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Orum, Vertex Ink Novel Protein-Deg
ScripFor Yuhan Corporation , the past several years have marked a new beginning in terms of the development and globalization of novel drugs, and the pursuit of an open innovation approach to R&D has been
ScripYuhan Corporation ’s first-in-class novel peptide drug candidate for degenerative disc disease (DDD), licensed out to US company Spine BioPharma in 2018, is now set to move into a Phase III trial in